AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

But in recent months, various media outlets and social media accounts have suggested taping your mouth closed before going to ...

Greater obstructive sleep apnea (OSA)-related hypoxemia is associated with frontoparietal cerebrovascular pathology, which is linked to reduced medial temporal lobe (MTL) integrity and impaired ...

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

Cambridge, USA-based Apnimed today announced positive top-line results from its pivotal Phase III SynAIRgy clinical trial evaluating the efficacy and safety of its lead candidate AD109 (aroxybutynin 2 ...

Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and acros ...

The main goal was to measure at six months the change in the apnea-hypopnea index, a scale used to measure the breathing reductions or interruptions during sleep (the higher the score, the more ...

An evaluation of 10 previously published studies suggests that a recent fad of taping one's mouth shut while sleeping to ...